Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 Program
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Affitope PD01 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors AFFiRiS
- 02 Jun 2017 Status changed from active, no longer recruiting to completed.
- 24 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
- 24 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.